Does the third generation targeted drug 9291 have side effects?

Of course, there is, and the common *** is diarrhea rash

If there is an adverse reaction, please seek medical attention in time, and the doctor will adjust the dose or usage of the targeted drug or discontinue the drug according to the degree of the adverse reaction.

Osimertinib, also known as AZD9291, is known as osimertinib. At present, there are several common manufacturers on the market: AstraZeneca (original research) in the United Kingdom, beacon in Bangladesh (imitation), Incepta in Bangladesh (imitation), and Lucius (imitation) in India.

- Indian Santodiva Medicine, cheap, conscientious, affordable.

9291 targeted drugs, the current use is ***. It's good for disease, but it's also big.

If there is a mutation, it means that the target is sensitive; If there is no mutation in the EGFR gene, targeting ** is poor. The first-line drugs targeting ** are gefitinib and trocae. If gefitinib or trocais is used, lung cancer** or disease progression, ostinib** may be considered and may also be effective.

The most common types of osartinib are diarrhea, rash, xerosis, nail toxicity, myocardial toxicity, leukopenia, or interstitial pneumonia.

3rd generation EGFR-TIK: AZD9291

The 2014 ASCO Annual Meeting will undoubtedly become a landmark year in the history of lung cancer, as it opens a new era of lung cancer targeting. Three powerful third-representative growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) emerged at this congress. Preliminary results from three Phase I clinical trials have shown remarkable efficacy, and some drugs have already begun to move towards Phase II and III clinical trials.

If we combine other targeted markers such as ALK, C-MET and FGFR, the next 10 years of targeted lung cancer targeting will definitely show us a dazzling era.

EGFR-TKI-sensitive EGFR gene mutations account for 40% of Asian non-small cell lung cancer (NSCLC) patients and 15% of European and American patients. EGFR-TTKI is currently approved for first-line use in advanced NSCLC with EGFR-TKI-sensitive mutations**. Significant rash and diarrhoea are due to its inhibition of wild-type EGFR.

Most patients with EGFR-mutant NSCLC eventually develop secondary resistance after receiving EGFR-TKI**. T790M mutation was detectable in 60% of EGFR-TKI-resistant tumors. There are currently no effective drugs in NSCLC that target the T790M mutation.

AZD9291 is a mutation-selective irreversible EGFR inhibitor, which has been shown to be effective against EGFR-TKI-sensitive and T790M-resistant mutations in tumor experimental models, and has weak selectivity for wild-type EGFR. AZD9291 has a terminal half-life of 55 h (30 145 h). Pharmacokinetics (PK) in Asian or non-Asian patients were consistent.

pasi a.An open-label, multicenter Phase I clinical trial led by Janne's team in Asian and Western patients with EGFR-TKI clinical benefit and radiographic progression in NSCLC. The study consisted of 5 dose groups:

20 mg, 40 mg, 80 mg, 160 mg, and 240 mg. The primary endpoint was safety and tolerability in patients resistant to EGFR-TKI. Secondary endpoints were to determine the maximum tolerated dose, pharmacokinetics, and preliminary efficacy.

The trial selects patients with EGFR-mutant NSCLC who are resistant to EGFR-TKI. Dose escalation and expansion cohort studies were included. AZD9291 is administered orally at a dose of 20 mg to 249 mg once daily.

Symptomatic stable brain metastases may be enrolled. The central laboratory detected the T790M mutation. As of April 2, 2014, a total of 232 patients (87 males, 145 females, median age 60 years, 65% Caucasian 32%, 57% recently EGFR-TKI**) were enrolled, 31 across 5 dose escalation levels, and 168 including 8 dose expansion cohorts.

All dose groups, including those with brain metastases, were effective. 132 cases were confirmed by the center as T7

There is nothing wrong with the saying that it is a medicine that is poisonous, and I hope you can do a good ** Don't give up if you are sick.

It's a medicine that is three parts poisonous, don't be afraid. As long as it can fight cancer and inhibit the growth of cancer cells, eat it.

That's good! Okay, go to sleep! Didn't you say that?